(Q33885386)

29 July 2017

1 reference

title

Current therapy for acromegaly (English)

1 reference

29 July 2017

Stewart PM

1

1 reference

29 July 2017

publication date

1 May 2000

1 reference

Trends in Endocrinology and Metabolism

29 July 2017

published in

1 reference

29 July 2017

volume

11

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

128-132

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

29 July 2017

1 reference

7 January 2021

Increased growth hormone pulse frequency in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Premature mortality due to cardiovascular disease in hypopituitarism

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Determinants of clinical outcome and survival in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Retrospective analysis of long-term surgical results in acromegaly: preoperative and postoperative factors predicting outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

A survey of results with transsphenoidal surgery in Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

A comparison of lanreotide and octreotide LAR for treatment of acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Octreotide as primary therapy for acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

Pituitary surgery for acromegaly. Should be done by specialists

1 reference

https://api.crossref.org/works/10.1016%2FS1043-2760%2800%2900244-7

7 January 2021

10.1016/S1043-2760(00)00244-7

Identifiers

DOI

1 reference

29 July 2017

1 reference